Taysha Gene Therapies (TSHA) Total Liabilities (2019 - 2026)

Taysha Gene Therapies has disclosed Total Liabilities across 8 years of filings, most recently posting $88.4 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $88.4 million, up 6.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $88.4 million (up 6.13% YoY), and the FY2025 annual result was $96.4 million, up 8.49% from the prior year.
• Total Liabilities came in at $88.4 million for Q1 2026 at Taysha Gene Therapies, down from $96.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $244.9 million in Q3 2023 to a low of $83.3 million in Q1 2025.
• The 5-year median for Total Liabilities is $97.8 million (2023), against an average of $108.8 million.
• Across the five-year window, Total Liabilities surged 477.5% in 2022 and slumped 62.67% in 2024, its largest moves.
• Taysha Gene Therapies' Total Liabilities stood at $125.3 million in 2022, then slipped by 21.97% to $97.8 million in 2023, then slipped by 9.16% to $88.8 million in 2024, then advanced by 8.49% to $96.4 million in 2025, then slipped by 8.27% to $88.4 million in 2026.
• The last three Total Liabilities figures came in at $88.4 million (Q1 2026), $96.4 million (Q4 2025), and $97.6 million (Q3 2025), per Business Quant data.